Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.
The authors evaluated the long-term efficacy and safety of botulinum toxin type A (BTX-A) in poststroke spasticity patients who completed a 12-week placebo-controlled study and received multiple open-label treatments with 200 to 240 U BTX-A for 42 weeks. Significant and sustained improvements were observed for Disability Assessment and Ashworth scores. Adverse events were generally mild. This extension of a double-blind study demonstrates that repeated treatments of BTX-A significantly improve function and tone in spasticity.
Gordon
M F
MF
North Shore/Long Island Jewish Health Systems, New Hyde Park, NY, USA. mfgordon@lij.edu
Brashear
A
A
Elovic
E
E
Kassicieh
D
D
Marciniak
C
C
Liu
J
J
Turkel
C
C
D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001132:Arm; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004185:Disability Evaluation; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009128:Muscle Spasticity / Q000188:drug therapy* / Q000209:etiology; D018908:Muscle Weakness / Q000139:chemically induced; D010147:Pain Measurement; D020127:Recovery of Function; D012720:Severity of Illness Index; D020521:Stroke / Q000150:complications*; D016896:Treatment Outcome
D019274:Botulinum Toxins, Type A